RETINOIC ACID RECEPTOR GAMMA AGONISTS TO ATTENUATE ANTHRACYCLINE-INDUCED CARDIOTOXICITY

摘要

Disclosed are methods, pharmaceutical compositions, kits, and systems for treating or preventing cardiotoxicity in a subject undergoing treatment with an anthracycline chemotherapeutic agent. The methods, pharmaceutical compositions, kits, and systems typically include or utilize an agonist of the retinoic acid receptor gamma (RARG).